Tower Research Capital (TRC)’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Tower Research Capital (TRC)’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,329	Closed	-$143K	–	6532
2023 Q1	$143K	Buy	1,329 +1,069	+411%	+$123K	﹤0.01%	1571
2022 Q4	$29K	Sell	260 -4,680	-95%	-$303K	﹤0.01%	2797
2022 Q3	$291K	Buy	4,940 +3,908	+379%	+$179K	﹤0.01%	1574
2022 Q2	$29K	Sell	1,032 -531	-34%	-$15.4K	﹤0.01%	3428
2022 Q1	$59K	Buy	1,563 +1,115	+249%	+$44.1K	﹤0.01%	2605
2021 Q4	$18K	Buy	448 +42	+10%	+$1.31K	﹤0.01%	3821
2021 Q3	$10K	Sell	406 -593	-59%	-$14K	﹤0.01%	4373
2021 Q2	$25K	Buy	+999	New	+$22.3K	﹤0.01%	3705

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Tower Research Capital (TRC)'s RXDX Position: Q2 2023 in Review

Tower Research Capital (TRC) sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,329 shares — an estimated $143K sold.

Tower Research Capital (TRC) first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $291K in Q3 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Tower Research Capital (TRC) reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 1,329 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $143K.
Tower Research Capital (TRC) first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Tower Research Capital (TRC)'s Prometheus Biosciences, Inc. Common Stock position peaked at $291K in Q3 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.